NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells

48Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

Purpose: Peripheral T-cell lymphomas (PTCL) are a heterogeneous entity of neoplasms with poor prognosis, a lack of effective therapies, and a largely unknown molecular pathology. Deregulated NF-κB activity has been associated with several lymphoproliferative diseases, but its importance in T-cell lymphomagenesis is poorly understood. We investigated the function of the NF-κB-inducing kinase (NIK), in this pathway and its role as a potential molecular target in T-cell lymphomas. Experimental Design: We used immunohistochemistry to analyze the expression of different NF-κB members in primary human PTCL samples and to study its clinical impact. With the aim of inhibiting the pathway, we used genetic silencing of NIK in several T-cell lymphoma cell lines and observed its effect on downstream targets and cell viability. Results: We showed that the NF-κB pathway was activated in a subset of PTCLs associated with poor overall survival. NIK was overexpressed in a number of PTCL cell lines and primary samples, and a pivotal role for NIK in the survival of these tumor cells was unveiled. NIK depletion led to a dramatic induction of apoptosis in NIK-overexpressing cell lines and also showed a more pronounced effect on cell survival than inhibitor of kappa B kinase (IKK) knockdown. NIK silencing induced a blockage of both classical and alternative NF-κB activation and reduced expression of several prosurvival and antiapoptotic factors. Conclusions: The results of the present study indicate that NIK could be a promising therapeutic target in these aggressive malignancies. ©2013 AACR.

Cite

CITATION STYLE

APA

Odqvist, L., Sańchez-Beato, M., Montes-Moreno, S., Martín-Sánchez, E., Pajares, R., Sánchez-Verde, L., … Piris, M. A. (2013). NIK controls classical and alternative NF-κB activation and is necessary for the survival of human T-cell lymphoma cells. Clinical Cancer Research, 19(9), 2319–2330. https://doi.org/10.1158/1078-0432.CCR-12-3151

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free